af-002 / Alpha Fusion - LARVOL DELTA

First-in-human evaluation of [211At]PSMA-5 as a novel targeted alpha therapy in patients with metastatic castration-resistant prostate cancer (mCRPC): Alpha-PS1 trial (ESMO 2026) - No abstract available

Clinical • First-in-human • Metastases • P1 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Alpha-PS1: Clinical Trial of Targeted Alpha Therapy Using [At-211]PSMA-5 for Prostate Cancer (clinicaltrials.gov) - P1 | N=15 | Active, not recruiting | Sponsor: Osaka University | Recruiting ➔ Active, not recruiting

Enrollment closed • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • CYP17A1